^
    2d
    A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer (clinicaltrials.gov)
    P2, N=43, Recruiting, Sun Yat-sen University | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
    Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • oxaliplatin
    2d
    Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread (clinicaltrials.gov)
    P1/2, N=768, Recruiting, Boehringer Ingelheim | N=582 --> 768 | Trial completion date: Sep 2029 --> Jan 2029 | Trial primary completion date: Sep 2029 --> Jan 2029
    Enrollment change • Trial completion date • Trial primary completion date
    |
    5-fluorouracil • Kadcyla (ado-trastuzumab emtansine) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • oxaliplatin • leucovorin calcium • Ziihera (zanidatamab-hrii) • Hernexeos (zongertinib)
    2d
    Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma (clinicaltrials.gov)
    P2, N=36, Recruiting, Sun Yat-sen University | Trial completion date: Nov 2025 --> Dec 2027 | Trial primary completion date: Nov 2024 --> Dec 2027
    Trial completion date • Trial primary completion date
    |
    Tyvyt (sintilimab) • capecitabine • Sulanda (surufatinib)
    2d
    DESTINY-Breast08: A Phase 1b Study of T-DXd Combinations in HER2-low Advanced or Metastatic Breast Cancer (clinicaltrials.gov)
    P1, N=138, Active, not recruiting, AstraZeneca | Trial completion date: Dec 2025 --> Jun 2026
    Trial completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)
    |
    HER-2 expression • HER-2 underexpression • PGR positive
    |
    Imfinzi (durvalumab) • paclitaxel • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine • fulvestrant • Truqap (capivasertib) • anastrozole
    3d
    FORTRESS: NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P1, N=30, Recruiting, Akamis Bio | Trial completion date: Jan 2029 --> May 2028 | Trial primary completion date: Feb 2026 --> May 2026
    Trial completion date • Trial primary completion date
    |
    capecitabine • NG-350A
    3d
    SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC (clinicaltrials.gov)
    P2, N=208, Recruiting, Shandong Provincial Hospital
    New P2 trial
    |
    capecitabine • oxaliplatin • AiRuiLi (adebrelimab)
    3d
    CIME: Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (clinicaltrials.gov)
    P3, N=132, Recruiting, Centre Leon Berard | Not yet recruiting --> Recruiting
    Enrollment open • Checkpoint inhibition • dMMR
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium • balstilimab (AGEN2034) • botensilimab (AGEN1181)
    4d
    Efficacy of fulvestrant and capecitabine as maintenance therapy in patients with HR +/HER2 - metastatic breast cancer benefited from first-line chemotherapy. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
    Metronomic CAP plus FUL can delay progressive disease (PD) and improve QoL in patients. Although these results are promising, they warrant further validation in larger, multicenter studies due to the limited sample size.
    Journal
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    capecitabine • fulvestrant
    4d
    AZUR-4: A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer (clinicaltrials.gov)
    P2, N=120, Recruiting, GlaxoSmithKline | Trial completion date: Jun 2028 --> Oct 2028 | Trial primary completion date: Jul 2026 --> Nov 2026
    Trial completion date • Trial primary completion date • Mismatch repair • pMMR
    |
    capecitabine • oxaliplatin • Jemperli (dostarlimab-gxly)
    4d
    Irinotecan Liposome Plus Capecitabine and Enronsubemab Combined With Short-course Radiotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cancer (clinicaltrials.gov)
    P2, N=30, Not yet recruiting, Tianjin Medical University Cancer Institute and Hospital
    New P2 trial
    |
    capecitabine
    4d
    A Phase Ib/II Trial of HS-20110 Combination Therapies in Advanced Colorectal Cancer Patients. (clinicaltrials.gov)
    P1/2, N=502, Not yet recruiting, Hansoh BioMedical R&D Company
    New P1/2 trial
    |
    Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
    4d
    FORTITUDE-102: Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. (clinicaltrials.gov)
    P3, N=515, Active, not recruiting, Amgen | Trial primary completion date: Jan 2026 --> Oct 2025
    Trial primary completion date
    |
    FGFR2 (Fibroblast growth factor receptor 2)
    |
    Opdivo (nivolumab) • 5-fluorouracil • capecitabine • oxaliplatin • bemarituzumab (AMG 552)